SureTrader
Interactive Brokers Advertisement
Home > Boards > Canadian > Biotechs > Medicenna Therapeutics (mdna)

Nice move yesterday ..

Public Reply | Private Reply | Keep | Last ReadPost New MsgPrevious | Next
BioSpecialist Member Profile
 
Followed By 105
Posts 1,822
Boards Moderated 7
Alias Born 12/27/07
160x600 placeholder
Medicenna Announces Trading on the OTCQX Best Market in the United States "PR Newswire (Canada)" - 10/18/2017 7:00:00 AM
OTC Markets Group Welcomes Medicenna Therapeutics to OTCQX "PR Newswire (US)" - 10/18/2017 7:00:00 AM
Medicenna Announces Trading on the OTCQX Best Market in the United States "PR Newswire (US)" - 10/18/2017 7:00:00 AM
Medicenna Presents Clinical Data on Initial Experience from Ongoing Phase 2b Study of MDNA55 "PR Newswire (Canada)" - 10/10/2017 10:49:00 AM
Medicenna Presents Clinical Data on Initial Experience from Ongoing Phase 2b Study of MDNA55 "PR Newswire (US)" - 10/10/2017 10:49:00 AM
Medicenna Updates On-Going Phase 2b Clinical Trial Protocol for Recurrent Glioblastoma "PR Newswire (Canada)" - 9/28/2017 4:30:00 PM
Medicenna Updates On-Going Phase 2b Clinical Trial Protocol for Recurrent Glioblastoma "PR Newswire (US)" - 9/28/2017 4:30:00 PM
Medicenna Announces Late Breaking Oral Presentation at the 2017 Congress of Neurological Surgeons (CNS) Annual Meeting "PR Newswire (Canada)" - 9/25/2017 7:00:00 AM
Medicenna Announces Late Breaking Oral Presentation at the 2017 Congress of Neurological Surgeons (CNS) Annual Meeting "PR Newswire (US)" - 9/25/2017 7:00:00 AM
Medicenna Appoints Dr. William Li to Board of Directors "PR Newswire (Canada)" - 9/21/2017 4:00:00 PM
Medicenna Appoints Dr. William Li to Board of Directors "PR Newswire (US)" - 9/21/2017 4:00:00 PM
Medicenna to Present at the 19th Annual Rodman & Renshaw Global Investment Conference "PR Newswire (Canada)" - 9/6/2017 7:19:00 AM
Medicenna to Present at the 19th Annual Rodman & Renshaw Global Investment Conference "PR Newswire (US)" - 9/6/2017 7:19:00 AM
Medicenna Reports First Quarter Fiscal 2018 Financial Results "PR Newswire (Canada)" - 8/9/2017 7:00:00 AM
Medicenna Reports First Quarter Fiscal 2018 Financial Results "PR Newswire (US)" - 8/9/2017 7:00:00 AM
BioSpecialist   Thursday, 09/21/17 10:27:25 AM
Re: None
Post # of 1 
Nice move yesterday ..

Small Phase 2b trial has huge chance to be successful because it was already successfull in prior studies so this stock like to be above $10 after phase 2 results in early Q1 . And that Management holding 15+ million shares of the 24.3 million shares outstanding makes me also optimistic .GL


MDNA55 is enrolling patients in a Phase 2b clinical trial for rGB at leading brain cancer centres in the US. MDNA55 has completed 3 clinical trials in 72 patients, including 66 adults with rGB, demonstrated compelling efficacy and obtained Fast-Track and Orphan Drug status from USFDA. Unlike most other cancer therapies, Medicenna's IL4-ECs have the potential to purge both the tumor and the immunosuppressive tumor microenvironment,


Medicenna Phase 2b trial using Brainlab technology
http://www.biotuesdays.com/briefs/2017/6/8/medicenna-phase-2b-trial-using-brainlab-technology

The current Phase 2b clinical trial plans to enroll 43 adult patients with rGB at leading brain cancer centers in the U.S.


Public Reply | Private Reply | Keep | Last ReadPost New MsgPrevious | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist